Identification of cell surface markers for acute myeloid leukemia prognosis based on multi-model analysis

Abstract

Given the extremely high inter-patient heterogeneity of acute myeloid leukemia (AML), the identification of biomarkers for prognostic assessment and therapeutic guidance is critical. Cell surface markers (CSMs) have been shown to play an important role in AML leukemogenesis and progression. In the current study, we evaluated the prognostic potential of all human CSMs in 130 AML patients from The Cancer Genome Atlas (TCGA) based on differential gene expression analysis and univariable Cox proportional hazards regression analysis. By using multi-model analysis, including Adaptive LASSO regression, LASSO regression, and Elastic Net, we constructed a 9-CSMs prognostic model for risk stratification of the AML patients. The predictive value of the 9-CSMs risk score was further validated at the transcriptome and proteome levels. Multivariable Cox regression analysis showed that the risk score was an independent prognostic factor for the AML patients. The AML patients with high 9-CSMs risk scores had a shorter overall and event-free survival time than those with low scores. Notably, single-cell RNA-sequencing analysis indicated that patients with high 9-CSMs risk scores exhibited chemotherapy resistance. Furthermore, PI3K inhibitors were identified as potential treatments for these high-risk patients. In conclusion, we constructed a 9-CSMs prognostic model that served as an independent prognostic factor for the survival of AML patients and held the potential for guiding drug therapy.

Keywords

acute myeloid leukemia / cell surface markers / prognosis / drug sensitivity / multi-model analysis

References

[1] DiNardo CD, Erba HP, Freeman SD, et al. Acute myeloid leukaemia[J]. Lancet, 2023, 401(10393): 2073-2086. doi: 10.1016/S0140-6736(23)00108-3

[2] De Kouchkovsky I, Abdul-Hay M. 'Acute myeloid leukemia: a comprehensive review and 2016 update'[J]. Blood Cancer J, 2016, 6(7): e441. doi: 10.1038/bcj.2016.50

[3] Pollyea DA, Jordan CT. Therapeutic targeting of acute myeloid leukemia stem cells[J]. Blood, 2017, 129(12): 1627-1635. doi: 10.1182/blood-2016-10-696039

[4] Vadakekolathu J, Minden MD, Hood T, et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia[J]. Sci Transl Med, 2020, 12(546): eaaz0463. doi: 10.1126/scitranslmed.aaz0463

[5] The Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia[J]. N Engl J Med, 2013, 368(22): 2059-2074. doi: 10.1056/NEJMoa1301689

[6] Zeng AGX, Bansal S, Jin L, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia[J]. Nat Med, 2022, 28(6): 1212-1223. doi: 10.1038/s41591-022-01819-x

[7] Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia[J]. Blood, 2010, 116(22): 4422-4429. doi: 10.1182/blood-2010-03-276485

[8] Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia[J]. N Engl J Med, 1999, 341(14): 1051-1062. doi: 10.1056/NEJM199909303411407

[9] Grob T, Sanders MA, Vonk CM, et al. Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia[J]. J Clin Oncol, 2023, 41(4): 756-765. doi: 10.1200/JCO.22.00715

[10] Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN[J]. Blood, 2022, 140(12): 1345-1377. doi: 10.1182/blood.2022016867

[11] Mercatelli D, Cabrelle C, Veltri P, et al. Detection of pan-cancer surface protein biomarkers via a network-based approach on transcriptomics data[J]. Brief Bioinform, 2022, 23(5): bbac400. doi: 10.1093/bib/bbac400

[12] Andrews TE, Wang D, Harki DA. Cell surface markers of cancer stem cells: diagnostic macromolecules and targets for drug delivery[J]. Drug Deliv Transl Res, 2013, 3(2): 121-142. doi: 10.1007/s13346-012-0075-1

[13] Hu Z, Yuan J, Long M, et al. The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets[J]. Nat Cancer, 2021, 2(12): 1406-1422. doi: 10.1038/s43018-021-00282-w

[14] Sadovnik I, Herrmann H, Blatt K, et al. Evaluation of cell surface markers and targets in leukemic stem cells (LSC) reveals distinct expression profiles, unique drug effects, and specific checkpoint regulation in AML LSC and CML LSC[J]. Blood, 2016, 128(22): 4234. doi: 10.1182/blood.V128.22.4234.4234

[15] Wu Z, Ou J, Liu N, et al. Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia[J]. Cancer Med, 2023, 12(7): 8956-8969. doi: 10.1002/cam4.5549

[16] Heitmann JS, Hagelstein I, Hinterleitner C, et al. Identification of CD318 (CDCP1) as novel prognostic marker in AML[J]. Ann Hematol, 2020, 99(3): 477-486. doi: 10.1007/s00277-020-03907-9

[17] Metzeler KH, Heilmeier B, Edmaier KE, et al. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia[J]. Blood, 2012, 120(10): 2118-2126. doi: 10.1182/blood-2012-02-411827

[18] Tibshirani R. Regression shrinkage and selection via the lasso[J]. J R Stat Soc Series B Stat Methodol, 1996, 58(1): 267-288. doi: 10.1111/j.2517-6161.1996.tb02080.x

[19] Zou H. The adaptive lasso and its oracle properties[J]. J Am Stat Assoc, 2006, 101(476): 1418-1429. doi: 10.1198/016214506000000735

[20] Tay JK, Narasimhan B, Hastie T. Elastic net regularization paths for all generalized linear models[J]. J Stat Softw, 2023, 106(1). doi: 10.18637/jss.v106.i01

[21] Butler A, Hoffman P, Smibert P, et al. Integrating single-cell transcriptomic data across different conditions, technologies, and species[J]. Nat Biotechnol, 2018, 36(5): 411-420. doi: 10.1038/nbt.4096

[22] Li K, Du Y, Cai Y, et al. Single-cell analysis reveals the chemotherapy-induced cellular reprogramming and novel therapeutic targets in relapsed/refractory acute myeloid leukemia[J]. Leukemia, 2023, 37(2): 308-325. doi: 10.1038/s41375-022-01789-6

[23] Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response[J]. Nat Med, 2018, 24(10): 1550-1558. doi: 10.1038/s41591-018-0136-1

[24] Fu J, Li K, Zhang W, et al. Large-scale public data reuse to model immunotherapy response and resistance[J]. Genome Med, 2020, 12(1): 21. doi: 10.1186/s13073-020-0721-z

[25] Yilmaz M, Kantarjian H, Ravandi F. Acute promyelocytic leukemia current treatment algorithms[J]. Blood Cancer J, 2021, 11(6): 123. doi: 10.1038/s41408-021-00514-3

[26] Zhang X, Sun J, Yu W, et al. Current views on the genetic landscape and management of variant acute promyelocytic leukemia[J]. Biomark Res, 2021, 9(1): 33. doi: 10.1186/s40364-021-00284-x

[27] Martelli AM, Nyåkern M, Tabellini G, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia[J]. Leukemia, 2006, 20(6): 911-928. doi: 10.1038/sj.leu.2404245

[28] Stefanidakis M, Karjalainen K, Jaalouk DE, et al. Role of leukemia cell invadosome in extramedullary infiltration[J]. Blood, 2009, 114(14): 3008-3017. doi: 10.1182/blood-2008-04-148643

[29] Fianchi L, Quattrone M, Criscuolo M, et al. Extramedullary involvement in acute myeloid leukemia. A single center ten years' experience[J]. Mediterr J Hematol Infect Dis, 2021, 13(1): e2021030. https://pubmed.ncbi.nlm.nih.gov/34007418/

[30] Sun Y, Berleth N, Wu W, et al. Fin56-induced ferroptosis is supported by autophagy-mediated GPX4 degradation and functions synergistically with mTOR inhibition to kill bladder cancer cells[J]. Cell Death Dis, 2021, 12(11): 1028. doi: 10.1038/s41419-021-04306-2

[31] Yu K, Shi C, Toral-Barza L, et al. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2[J]. Cancer Res, 2010, 70(2): 621-631. doi: 10.1158/0008-5472.CAN-09-2340

[32] Bei S, Li F, Li H, et al. Inhibition of gastric cancer cell growth by a PI3K-mTOR dual inhibitor GSK1059615[J]. Biochem Biophys Res Commun, 2019, 511(1): 13-20. doi: 10.1158/1535-7163.MCT-17-1178

[33] Ramchandren R, Domingo-Domènech E, Rueda A, et al. Nivolumab for newly diagnosed advanced-stage classic hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study[J]. J Clin Oncol, 2019, 37(23): 1997-2007. doi: 10.1200/JCO.19.00315

[34] Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD[J]. Blood, 2017, 130(2): 221-228. doi: 10.1182/blood-2017-01-761346

[35] Meric-Bernstam F, Larkin J, Tabernero J, et al. Enhancing anti-tumour efficacy with immunotherapy combinations[J]. Lancet, 2021, 397(10278): 1010-1022. doi: 10.1016/S0140-6736(20)32598-8

[36] Barreyro L, Will B, Bartholdy B, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS[J]. Blood, 2012, 120(6): 1290-1298. doi: 10.1182/blood-2012-01-404699

[37] Teijeira Á, Garasa S, Gato M, et al. CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity[J]. Immunity, 2020, 52(5): 856-871. e8.

[38] Cheng Y, Mo F, Li Q, et al. Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin[J]. Mol Cancer, 2021, 20(1): 62. doi: 10.1186/s12943-021-01355-1

[39] AlHossiny M, Luo L, Frazier WR, et al. Ly6E/K signaling to TGFβ promotes breast cancer progression, immune escape, and drug resistance[J]. Cancer Res, 2016, 76(11): 3376-3386. doi: 10.1158/0008-5472.CAN-15-2654

[40] Tu TC, Brown NK, Kim TJ, et al. CD160 is essential for NK-mediated IFN-γ production[J]. J Exp Med, 2015, 212(3): 415-429. doi: 10.1084/jem.20131601

[41] Hao W, Yu M, Lin J, et al. The pan-cancer landscape of netrin family reveals potential oncogenic biomarkers[J]. Sci Rep, 2020, 10(1): 5224. doi: 10.1038/s41598-020-62117-5